Early investigation of a novel SI306 theranostic prodrug for glioblastoma treatment.
Src inhibitors
glioblastoma multiforme
theranostic agents
Journal
Drug development research
ISSN: 1098-2299
Titre abrégé: Drug Dev Res
Pays: United States
ID NLM: 8204468
Informations de publication
Date de publication:
Feb 2024
Feb 2024
Historique:
revised:
14
12
2023
received:
08
11
2023
accepted:
22
01
2024
medline:
13
2
2024
pubmed:
13
2
2024
entrez:
13
2
2024
Statut:
ppublish
Résumé
Glioblastoma multiforme (GBM) is one of the most aggressive malignancies with a high recurrence rate and poor prognosis. Theranostic, combining therapeutic and diagnostic approaches, arises as a successful strategy to improve patient outcomes through personalized medicine. Src is a non-receptor tyrosine kinase (nRTK) whose involvement in GBM has been extensively demonstrated. Our previous research highlighted the effectiveness of the pyrazolo[3,4-d]pyrimidine SI306 and its more soluble prodrug CMP1 as Src inhibitors both in in vitro and in vivo GBM models. In this scenario, we decided to develop a theranostic prodrug of SI306, ProSI-DOTA(
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e22158Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : GrantIG-2019
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : Project code 23725
Organisme : Prin2017
ID : PRIN2017SA5837
Organisme : PNRR-NextGenerationEU
ID : IR0000023
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
AbdEl-haq, M., Kumar, A., Ait Mohand, F., Kravchenko-Balasha, N., Rottenberg, Y., & Domb, A. J. (2023). Paclitaxel delivery to the brain for glioblastoma treatment. International Journal of Molecular Sciences, 24(14), 14. https://doi.org/10.3390/ijms241411722
Agarwal, S., Mittapalli, R. K., Zellmer, D. M., Gallardo, J. L., Donelson, R., Seiler, C., Decker, S. A., Santacruz, K. S., Pokorny, J. L., Sarkaria, J. N., Elmquist, W. F., & Ohlfest, J. R. (2012). Active efflux of dasatinib from the brain limits efficacy against murine glioblastoma: Broad implications for the clinical use of molecularly targeted agents. Molecular Cancer Therapeutics, 11(10), 2183-2192. https://doi.org/10.1158/1535-7163.MCT-12-0552
Ahluwalia, M. S., Groot, J., Liu, W., & Gladson, C. L. (2010). Targeting SRC in glioblastoma tumors and brain metastases: Rationale and preclinical studies. Cancer Letters, 298(2), 139-149. https://doi.org/10.1016/j.canlet.2010.08.014
Ballinger, J. R. (2018). Theranostic radiopharmaceuticals: Established agents in current use. The British Journal of Radiology, 91(1091), 20170969. https://doi.org/10.1259/bjr.20170969
Baranyai, Z., Tircsó, G., & Rösch, F. (2020). The use of the macrocyclic chelator DOTA in radiochemical separations. European Journal of Inorganic Chemistry, 2020(1), 36-56. https://doi.org/10.1002/ejic.201900706
Brai, A., Riva, V., Saladini, F., Zamperini, C., Trivisani, C. I., Garbelli, A., Pennisi, C., Giannini, A., Boccuto, A., Bugli, F., Martini, M., Sanguinetti, M., Zazzi, M., Dreassi, E., Botta, M., & Maga, G. (2020). DDX3X inhibitors, an effective way to overcome HIV-1 resistance targeting host proteins. European Journal of Medicinal Chemistry, 200, 112319. https://doi.org/10.1016/j.ejmech.2020.112319
Calgani, A., Vignaroli, G., Zamperini, C., Coniglio, F., Festuccia, C., Di Cesare, E., Gravina, G. L., Mattei, C., Vitale, F., Schenone, S., Botta, M., & Angelucci, A. (2016). Suppression of SRC signaling is effective in reducing synergy between glioblastoma and stromal cells. Molecular Cancer Therapeutics, 15(7), 1535-1544. https://doi.org/10.1158/1535-7163.MCT-15-1011
Ceccherini, E., Indovina, P., Zamperini, C., Dreassi, E., Casini, N., Cutaia, O., Forte, I. M., Pentimalli, F., Esposito, L., Polito, M. S., Schenone, S., Botta, M., & Giordano, A. (2015). SRC family kinase inhibition through a new pyrazolo[3,4-d]pyrimidine derivative as a feasible approach for glioblastoma treatment: SFK targeting in glioblastoma cells. Journal of Cellular Biochemistry, 116(5), 856-863. https://doi.org/10.1002/jcb.25042
Chen, Y., Agarwal, S., Shaik, N. M., Chen, C., Yang, Z., & Elmquist, W. F. (2009). P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib. Journal of Pharmacology and Experimental Therapeutics, 330(3), 956-963. https://doi.org/10.1124/jpet.109.154781
Cirotti, C., Contadini, C., & Barilà, D. (2020). SRC kinase in glioblastoma news from an old acquaintance. Cancers, 12(6), 1558. https://doi.org/10.3390/cancers12061558
Du, J., Bernasconi, P., Clauser, K. R., Mani, D. R., Finn, S. P., Beroukhim, R., Burns, M., Julian, B., Peng, X. P., Hieronymus, H., Maglathlin, R. L., Lewis, T. A., Liau, L. M., Nghiemphu, P., Mellinghoff, I. K., Louis, D. N., Loda, M., Carr, S. A., Kung, A. L., & Golub, T. R. (2009). Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nature Biotechnology, 27(1), 77-83. https://doi.org/10.1038/nbt.1513
Esemen, Y., Awan, M., Parwez, R., Baig, A., Rahman, S., Masala, I., Franchini, S., & Giakoumettis, D. (2022). Molecular pathogenesis of glioblastoma in adults and future perspectives: A systematic review. International Journal of Molecular Sciences, 23(5), 2607. https://doi.org/10.3390/ijms23052607
Fallacara, A. L., Zamperini, C., Podolski-Renić, A., Dinić, J., Stanković, T., Stepanović, M., Mancini, A., Rango, E., Iovenitti, G., Molinari, A., Bugli, F., Sanguinetti, M., Torelli, R., Martini, M., Maccari, L., Valoti, M., Dreassi, E., Botta, M., Pešić, M., & Schenone, S. (2019). A new strategy for glioblastoma treatment: In vitro and in vivo preclinical characterization of Si306, a pyrazolo[3,4-d]pyrimidine dual Src/P-glycoprotein inhibitor. Cancers, 11(6), 848. https://doi.org/10.3390/cancers11060848
Gomes Marin, J. F., Nunes, R. F., Coutinho, A. M., Zaniboni, E. C., Costa, L. B., Barbosa, F. G., Queiroz, M. A., Cerri, G. G., & Buchpiguel, C. A. (2020). Theranostics in nuclear medicine: Emerging and re-emerging integrated imaging and therapies in the era of precision oncology. Radiographics, 40(6), 1715-1740. https://doi.org/10.1148/rg.2020200021
Grochans, S., Cybulska, A. M., Simińska, D., Korbecki, J., Kojder, K., Chlubek, D., & Baranowska-Bosiacka, I. (2022). Epidemiology of glioblastoma multiforme-literature review. Cancers, 14(10), 2412. https://doi.org/10.3390/cancers14102412
Hanson, L. R., & Frey, W. H. (2008). Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neuroscience, 9(3), S5. https://doi.org/10.1186/1471-2202-9-S3-S5
Holik, H. A., Ibrahim, F. M., Elaine, A. A., Putra, B. D., Achmad, A., & Kartamihardja, A. H. S. (2022). The chemical scaffold of theranostic radiopharmaceuticals: Radionuclide, bifunctional chelator, and pharmacokinetics modifying linker. Molecules, 27(10), Articolo 10. https://doi.org/10.3390/molecules27103062
James, M. L., & Gambhir, S. S. (2012). A molecular imaging primer: Modalities, imaging agents, and applications. Physiological Reviews, 92(2), 897-965. https://doi.org/10.1152/physrev.00049.2010
Jeelani, S., Reddy, R. C., Maheswaran, T., Asokan, G. S., Dany, A., & Anand, B. (2014). Theranostics: A treasured tailor for tomorrow. Journal of Pharmacy & Bioallied Sciences, 6(Suppl 1), 6-8. https://doi.org/10.4103/0975-7406.137249
Khabibov, M., Garifullin, A., Boumber, Y., Khaddour, K., Fernandez, M., Khamitov, F., Khalikova, L., Kuznetsova, N., Kit, O., & Kharin, L. (2022). Signaling pathways and therapeutic approaches in glioblastoma multiforme (review). International Journal of Oncology, 60(6), 69. https://doi.org/10.3892/ijo.2022.5359
Khasraw, M., Fujita, Y., Lee-Chang, C., Balyasnikova, I. V., Najem, H., & Heimberger, A. B. (2022). New approaches to glioblastoma. Annual Review of Medicine, 73, 279-292. https://doi.org/10.1146/annurev-med-042420-102102
Kim, M. M., Umemura, Y., & Leung, D. (2018). Bevacizumab and glioblastoma: Past, present, and future directions. The Cancer Journal, 24(4), 180-186. https://doi.org/10.1097/PPO.0000000000000326
Kostić, A., Jovanović Stojanov, S., Podolski-Renić, A., Nešović, M., Dragoj, M., Nikolić, I., Tasić, G., Schenone, S., Pešić, M., & Dinić, J. (2021). Pyrazolo[3,4-d]pyrimidine tyrosine kinase inhibitors induce oxidative stress in patient-derived glioblastoma cells. Brain Sciences, 11(7), 884. https://doi.org/10.3390/brainsci11070884
Le Rhun, E., Preusser, M., Roth, P., Reardon, D. A., van den Bent, M., Wen, P., Reifenberger, G., & Weller, M. (2019). Molecular targeted therapy of glioblastoma. Cancer Treatment Reviews, 80, 101896. https://doi.org/10.1016/j.ctrv.2019.101896
Maharvi, G. M., Bharucha, A. E., & Fauq, A. H. (2013). Synthesis of a DOTA (Gd3+)-conjugate of proton-pump inhibitor pantoprazole for gastric wall imaging studies. Bioorganic & Medicinal Chemistry Letters, 23(9), 2808-2811. https://doi.org/10.1016/j.bmcl.2012.06.051
Monteleone, L., Marengo, B., Musumeci, F., Grossi, G., Carbone, A., Valenti, G. E., Domenicotti, C., & Schenone, S. (2022). Anti-survival effect of SI306 and its derivatives on human glioblastoma cells. Pharmaceutics, 14(7), 1399. https://doi.org/10.3390/pharmaceutics14071399
Nešović, M., Divac Rankov, A., Podolski-Renić, A., Nikolić, I., Tasić, G., Mancini, A., Schenone, S., Pešić, M., & Dinić, J. (2020). Src inhibitors pyrazolo[3,4-d]pyrimidines, Si306 and Pro-Si306, inhibit focal adhesion kinase and suppress human glioblastoma invasion in vitro and in vivo. Cancers, 12(6), 1570. https://doi.org/10.3390/cancers12061570
Oronsky, B., Reid, T. R., Oronsky, A., Sandhu, N., & Knox, S. J. (2021). A review of newly diagnosed glioblastoma. Frontiers in Oncology, 10, 574012. https://doi.org/10.3389/fonc.2020.574012
Poggialini, F., Vagaggini, C., Brai, A., Pasqualini, C., Crespan, E., Maga, G., Perini, C., Cabella, N., Botta, L., Musumeci, F., Frosini, M., Schenone, S., & Dreassi, E. (2023). Biological evaluation and in vitro characterization of ADME profile of in-house pyrazolo[3,4-d]pyrimidines as dual tyrosine kinase inhibitors active against glioblastoma multiforme. Pharmaceutics, 15(2), 2. https://doi.org/10.3390/pharmaceutics15020453
Radi, M., Dreassi, E., Brullo, C., Crespan, E., Tintori, C., Bernardo, V., Valoti, M., Zamperini, C., Daigl, H., Musumeci, F., Carraro, F., Naldini, A., Filippi, I., Maga, G., Schenone, S., & Botta, M. (2011). Design, synthesis, biological activity, and ADME properties of pyrazolo[3,4-d]pyrimidines active in hypoxic human leukemia cells: A lead optimization study. Journal of Medicinal Chemistry, 54(8), 2610-2626. https://doi.org/10.1021/jm1012819
Roda, E., & Bottone, M. G. (2022). Editorial: Brain cancers: New perspectives and therapies. Frontiers in Neuroscience, 16, 857408. https://doi.org/10.3389/fnins.2022.857408
Seelam, S. R., Lee, Y.-S., & Jeong, J. M. (2016). Chelators for 68Ga radio-pharmaceuticals. Journal of Radiopharmaceuticals and Molecular Probes, 2(1), 22-36.
Semyachkina-Glushkovskaya, O., Shirokov, A., Blokhina, I., Telnova, V., Vodovozova, E., Alekseeva, A., Boldyrev, I., Fedosov, I., Dubrovsky, A., Khorovodov, A., Terskov, A., Evsukova, A., Elovenko, D., Adushkina, V., Tzoy, M., Agranovich, I., Kurths, J., & Rafailov, E. (2022). Intranasal delivery of liposomes to glioblastoma by photostimulation of the lymphatic system. Pharmaceutics, 15(1), 36. https://doi.org/10.3390/pharmaceutics15010036
Sukumar, U. K., Bose, R. J. C., Malhotra, M., Babikir, H. A., Afjei, R., Robinson, E., Zeng, Y., Chang, E., Habte, F., Sinclair, R., Gambhir, S. S., Massoud, T. F., & Paulmurugan, R. (2019). Intranasal delivery of targeted polyfunctional gold-iron oxide nanoparticles loaded with therapeutic microRNAs for combined theranostic multimodality imaging and presensitization of glioblastoma to temozolomide. Biomaterials, 218, 119342. https://doi.org/10.1016/j.biomaterials.2019.119342
Tan, A. C., Ashley, D. M., López, G. Y., Malinzak, M., Friedman, H. S., & Khasraw, M. (2020). Management of glioblastoma: State of the art and future directions. CA: A Cancer Journal for Clinicians, 70(4), 299-312. https://doi.org/10.3322/caac.21613
Taylor, O. G., Brzozowski, J. S., & Skelding, K. A. (2019). Glioblastoma multiforme: An overview of emerging therapeutic targets. Frontiers in Oncology, 9, 963. https://doi.org/10.3389/fonc.2019.00963
Veronesi, M. C., Alhamami, M., Miedema, S. B., Yun, Y., Ruiz-Cardozo, M., & Vannier, M. W. (2020). Imaging of intranasal drug delivery to the brain. American Journal of Nuclear Medicine and Molecular Imaging, 10(1), 1-31.
Vignaroli, G., Iovenitti, G., Zamperini, C., Coniglio, F., Calandro, P., Molinari, A., Fallacara, A. L., Sartucci, A., Calgani, A., Colecchia, D., Mancini, A., Festuccia, C., Dreassi, E., Valoti, M., Musumeci, F., Chiariello, M., Angelucci, A., Botta, M., & Schenone, S. (2017). Prodrugs of pyrazolo[3,4-d]pyrimidines: From library synthesis to evaluation as potential anticancer agents in an orthotopic glioblastoma model. Journal of Medicinal Chemistry, 60(14), 6305-6320. https://doi.org/10.1021/acs.jmedchem.7b00637
Vignaroli, G., Zamperini, C., Dreassi, E., Radi, M., Angelucci, A., Sanità, P., Crespan, E., Kissova, M., Maga, G., Schenone, S., Musumeci, F., & Botta, M. (2013). Pyrazolo[3,4-d]pyrimidine prodrugs: Strategic optimization of the aqueous solubility of dual Src/Abl inhibitors. ACS Medicinal Chemistry Letters, 4(7), 622-626. https://doi.org/10.1021/ml4000782
Weis, S., Cui, J., Barnes, L., & Cheresh, D. (2004). Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. The Journal of Cell Biology, 167(2), 223-229. https://doi.org/10.1083/jcb.200408130
Weissenberger, J., Steinbach, J. P., Malin, G., Spada, S., Rülicke, T., & Aguzzi, A. (1997). Development and malignant progression of astrocytomas in GFAP-v-src transgenic mice. Oncogene, 14(17), 2005-2013. https://doi.org/10.1038/sj.onc.1201168
Wen, P. Y., Stein, A., van den Bent, M., De Greve, J., Wick, A., de Vos, F. Y. F. L., von Bubnoff, N., van Linde, M. E., Lai, A., Prager, G. W., Campone, M., Fasolo, A., Lopez-Martin, J. A., Kim, T. M., Mason, W. P., Hofheinz, R.-D., Blay, J.-Y., Cho, D. C., Gazzah, A., & ubbiah, V. (2022). Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): A multicentre, open-label, single-arm, phase 2, basket trial. The Lancet Oncology, 23(1), 53-64. https://doi.org/10.1016/S1470-2045(21)00578-7